Biohaven has entered into an exclusive worldwide license agreement with Catalent U.K. Swindon Zydis Limited, a subsidiary of Catalent to provide Catalent's Zydis ODT (orally disintegrating tablet) fast-dissolving formulation for the development of Biohaven's lead calcitonin gene-related peptide (CGRP) receptor antagonist product candidate, rimegepant. The agreement also provides exclusive rights for developing small molecule CGRP receptor antagonists with the Zydis ODT technology. Catalent's proprietary Zydis technology is a unique, freeze-dried, oral solid dosage form that disperses almost instantly in the mouth, without the need for water.
"This exclusive agreement with Catalent now adds the world's leading ODT formulation to our CGRP receptor antagonist platform. Fast-dissolve formulations are particularly well suited for people with migraine,” Vlad Coric, M.D., Chief Executive Officer of Biohaven, said. “Migraine patients need to take acute treatments promptly, whenever and wherever an attack hits. People with migraine often have accompanying nausea and have an aversion to consuming food or liquids during an attack. The Zydis ODT formulation uniquely addresses this issue by allowing such patients to take a fast-dissolving tablet without water."